" class="no-js "lang="en-US"> Arturo Molina - Medtech Alert
Friday, April 25, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Arturo Molina

Arturo Molina

About Arturo Molina

Experienced Chief Medical Officer with a demonstrated history of working in the biotechnology industry. Skilled in Pharmaceutics, Biomarkers, Translational Medicine, Oncology, and Hematology. Strong healthcare services professional graduated from Stanford University School of Medicine. Practicing oncologist/hematologist, volunteer staff physician at the Palo Alto VA Hospital, a Stanford-affiliate teaching hospital.

Related Story

Appointments

 Sutro Biopharma Announces Expansion of Leadership Team | Pharmtech Focus

Sutro Biopharma Announces Expansion of Leadership Team

September 17 2021

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on […]